CHAPTER-7 Development and Validation of a RP-HPLC method for related compund-c in Ziprasidone hydrochloride monohydrate
|
|
- Ross Fisher
- 6 years ago
- Views:
Transcription
1 CHAPTER-7 Development and Validation of a RP-HPLC method for related compund-c in Ziprasidone hydrochloride monohydrate Chapter-7 Page 212
2 7.1. INTRODUCTION This chapter describes about the Development and validation of a RP-HPLC method for related compound-c in Ziprasidone hydrochloride monohydrate, survey of literature, materials and methods, results and discussion, summary and conclusion were covered. Ziprasidone hydrochloride monohydrate 5-[2-[4-(1,2- benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one is the treatment of schizophrenia, and acute mania and mixed states associated with bipolar disorder. Its intramuscular injection form is approved for acute agitation in schizophrenic patients for whom treatment with just Ziprasidone hydrochloride monohydrate is appropriate. Analytical HPLC method has been developed for Ziprasidone hydrochloride monohydrate and impurities. Many HPLC, LC-MS and UPLC methods are observed in publications during method development. An HPLC method is developed for Ziprasidone hydrochloride monohydrate (1 1-11) and related compound-c. Figure- 7.1: Structure of Ziprasidone hydrochloride monohydrate. Chemical name : 5-[2-[4-(1,2-benzisothiazol-3-yl)-1- piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2- one CAS Registry Number : Chapter-7 Page 213
3 Molecular formula : C21H21 CLN4OS Molecular weight : Therapeutic category : Schizophrenia and acute mania Table- 7.1: Ziprasidone hydrochloride monohydrate impurities details: S. No Impurity structure Chemical name Molecular weight Related compound-c 1 Methyl (-)-(R)-(o- chlorophenyl)- 6,7-dihyrothieno [3,2-c] pyridine-5 (4H)- acetate, hydrogen sulfate C42H40Cl2N8O5S2 Related compound-d 2 (3- (benzo[d]isothiazol- 3-yl)-5-(2-(4- (benzo[d] isothiazol-3- yl)piperazil-1-yl) ethyl)-6- chloroindolin-2-one) C28H24 ClN5OS2 Chapter-7 Page 214
4 ZPH Acetone 5-(2-(4-3. O HN N N (benzo[d]isothiazol- 3-yl)piperazin-1- yl)ethyl)-6-chloro C24H25ClN4OS Cl N S (prop-1-en-2- yl)indolin-2-one 7.2. REVIEW OF LITERATURE A simple and reliable head space gas chromatographic method has been developed for the determination of residual methyl chloride, ethyl chloride and isopropyl chloride in Ziprasidone hydrochloride monohydrate. The proposed method is based on flame ionization detection technique with DB-624 as stationary phase. Linearity of detector response was established up to 13.5μg/g and the detection limit was 0.8μg/g for methyl chloride, ethyl chloride and 0.9μg/g for isopropyl chloride respectively. No interference of organic solvents used in the synthesis was observed. Performance of the method was assessed by evaluating the recovery, repeatability, reproducibility, linearity and limits of detection and quantification. The proposed method has a potential for application to drug substances which may contains traces of alkyl chloride. Results prove that the validated method was suitable for determining the residual methyl chloride, ethyl chloride and isopropyl chloride in Ziprasidone hydrochloride monohydrate drug substance. To widen the scope of this method, interference of 17 commonly employed solvents in the synthesis has been studied for any possible interference with methyl chloride, ethyl chloride and isopropyl chloride. The potentiality of method has been studied for various drug substances containing possible alkyl chlorides residue present in their drug matrix. Chapter-7 Page 215
5 Ultra Performance Liquid Chromatography (UPLC) was employed to develop a rapid and robust method for the analysis of Ziprasidone hydrochloride monohydrate, both as a drug substance and in the final dosage forms. The application of this method in stability analyses was verified. Tests were carried out according to ICH/FDA guidelines, European Pharmacopeia, and United States Pharmacopeia rules, which take into account factors such as specificity, linearity, accuracy, and precision. Separation was performed on an acquity UPLC BEH phenyl 1.7μm column with a simple mobile phase, consisting of acetonitrile and water adjusted to ph 2.0 with ortho-phosphoric acid. Using this mobile phase and gradient elution, the separation was completed with in 5 min. This method is very sensitive, and allows performing simultaneous identification, assay, and determination of impurities and related substances in one injection. A reverse phase HPLC method is described for the determination of Ziprasidone hydrochloride monohydrate in bulk and pharmaceutical dosage forms. Chromatography was carried out on an ODS C18 column using a mixture of methanol and phosphate buffer (55:45 v/v) as the mobile phase at a flow rate of 1mL/min. Detection was carried out at 314nm. The retention time of the drug was min. The method produced linear responses in the concentration range of μg /ml of Ziprasidone hydrochloride monohydrate. The method was found to be applicable for determination of the drug in capsules. Ziprasidone is known as a novel "a typical" or "second-generation" antipsychotic drug. A sensitive and reproducible method was developed and validated for determination of Ziprasidone hydrochloride monohydrate and its major impurities, which are significantly different in polarity. The separation is performed on a Waters spherisorb octadecylsilyl column (5.0 μm, 250 x 4.6 mm I.D.) using a gradient with mobile phase A [buffer:acetonitrile] [80:20, v/v] and mobile phase B [buffer:acetonitrile] [10:90, v/v] at a working temperature of 25 C. The buffer was 0.05 M KH2PO4 solution with an addition of 10 ml triethylamine /Lsolution, adjusted to ph 2.5 with ortho phosphoric acid. The flow rate was 1.5 ml/min, and the elute was monitored at 250 nm using a diode array detector. Chapter-7 Page 216
6 Optimization of the experimental conditions was performed using partial least squares regression, for which four factors were selected for optimization: buffer concentration, buffer ph, triethylamine concentration, and temperature. The proposed validated method is convenient and reliable for the assay and purity control in both raw materials and dosage forms OBJECTIVE The main objective of this research work is to develop method for separation of related compound-c and Ziprasidone Acetone impurity in Ziprasidone hydrochloride monohydrate. After review of so many literature is reveals that the reported methods are not reported for the separation of these two impurities in any where MATERIALS AND METHODS Reagents & Chemicals. a. Water : Merck b. Acetonitrile HPLC grade : Merck c. Mono basic potassium phosphate : Merck d. Potassium hydroxide : Merck e. Methanol : Merck f. Hydrochloric acid : Merck Drug substances: Ziprasidone hydrochloride monohydrate and related compound-c and related compound-d samples were received from M/S Aurobindo Laboratories, Hyderabad(A.P),India. Chapter-7 Page 217
7 Instrument details: The High performance Liquid Chromatography using Waters HPLC instrument having quaternary pumps including auto injector. This HPLC connected with PDA detector, make Waters. All the components are controlled with Empower2 software Method development: Development trials were performed with all neutral buffer salts and different make HPLC columns but finally the chromatographic conditions were optimized with the potassium phosphate salt, acetonitrile and methanol with simple gradient program Wave length Selection: The UV spectrums were generated for Ziprasidone hydrochloride monohydrate and related compound-c using with photo diode array detector (PDA). Ziprasidone hydrochloride monohydrate and its impurities were found to have varying absorption maxima over a range of wave length. But it was found that at about 229nm, Ziprasidone hydrochloride monohydrate and its impurities were found to have optimum UV absorption. Therefore, 229nm was selected for the study and quantification of Ziprasidone hydrochloride monohydrate and it s related impurities. Figure- 7.2: UV Spectra of (a) Ziprasidone hydrochloride monohydrate, (b) related compound-c (c) related compound-d. Chapter-7 Page 218
8 Selection of mobile phase and stationary phase: Ziprasidone hydrochloride monohydrate and related compound-c were found that different functional groups, shows different affinities with mobile phases and stationary phase. A different column with different selectivity provides good separation for method development. Two parameters were chosen to get required resolutions and separations and symmetrical peaks for Ziprasidone hydrochloride monohydrate and impurities. i.e., Selection of the mobile phase and column Selection of Mobile phase: Ziprasidone hydrochloride monohydrate acetone, related compound-c were co-eluted using with different mobile phases. Ziprasidone hydrochloride monohydrate and the impurities of Ziprasidone hydrochloride monohydrate were having wide range of polarities and the separation of these impurities mainly depends on the column stationary phase. An gradient method was mobile phase of buffer is 0.02M ammonium dihydrogen phosphate in water ph adjusted to 9.85 and acetonitrile and methanol was suitable for the separation of Ziprasidone hydrochloride monohydrate and its related substances. Mobile phase was degassed and filtered through 0.22 µm millipore filter paper Selection of stationary phase: Separation was achieved with Zorbax RX C8 150 x 4.6 mm I.D.,5.0µm column. Different stationary phases were studies for the separation of Ziprasidone hydrochloride monohydrate such as C18 and C8 using the mobile phase specified. The experimentation was started using Waters Symmetry C18, 250 x 4.6mm,I.D., 5.0µm, column. Trail-1: The complete experiment details are as follows. Column : Waters symmetry C18, 250 x 4.6mm I.D.,5.0µm Mobile Phase-A : 0.25% phosphoric acid mixed 2.50 g of ortho phosphoric acid in 1000 ml of water. Mixed well, filtered and degassed Chapter-7 Page 219
9 Mobile phase-b Sample Preparation : Flow rate Oven temperature Injection volume Elution : Mixed acetonitrile and water in the ratio of 95 and 5 and sonicate to degassed 0.5mg/mL : 0.9 ml/ min : 30 o C : 20µL : Gradient Gradient program Time in min Mobilephase- A Mobilephase- (%) B (%) Figure-7.3: Blend Chromatogram by using waters Symmetry C18, 250 x 4.6mm I.D., 5.0µm column and trail-1 method conditions. Chapter-7 Page 220
10 Observation: Related compound-c is not stable in trail-1method conditions, hence waters symmetry C18, 250 x 4.6mm,I.D., 5.0µm, column and trail-1 method conditions not suitable for the separation of related compound-c. Trail-2: The complete experiment details are as follows. Column Buffer : : Zorbax RX C8 150 x 4.6 mm I.D., 5.0µm column Dissolved 6.8 g/l of monobasic potassium phosphate in water and adjust with 5N potassium hydroxide to a ph of 6.0 Mobile Phase : Acetonitrile: methanol : buffer ( 11:1:8) Wavelength : 229 nm Flow rate Diluent Elution : : : 1.0 ml/min Methanol, water and hydrochloric acid (20:5:0.01) Isocratic Sample preparation Injection volume Run time : : : 0.5mg/mL 20µL 60min Figure-7.4: Blend Chromatogram by using Zorbax RX C8 150 X 4.6 mmi.d., 5.0µm column and trail-2 method conditions. Chapter-7 Page 221
11 Observation: Related compound-c and ZPH Acetone are coeluting. Hence, the isocratic elution and trail-2 method conditions is not suitable for the separation of related compound-c. Trail-3: The complete experiment details are as follows. Column Buffer(Mobile phase-a) : Zorbax RX C8 150 x 4.6 mm I.D., 5.0μm column : Dissolve 6.8 g/l of monobasic potassium phosphate in water and adjust with 5N potassium hydroxide to a ph of 6.0 Mobile phase-b : Buffer and acetonitrile in the ratio of 75:25 v/v Sample preparation : 5 mg in 25 ml of diluent Wavelength : 229 nm Flow rate : 1.0 ml/ min Oven temperature : 40 o C Diluent Elution Injection volume Runtime : 100% acetonotrile : Gradient : 20μL : 60 min Gradient program Mobile phase- Mobile phase B Time in min A(%) (%) Chapter-7 Page 222
12 Figure-7.5: Blend Chromatogram by using Zorbax RX C8 150 X 4.6 mm I.D., 5.0µm column and trail-3 method conditions. Conclusion: Method needs to modify for getting to reduce blank peaks and baseline noise. Based on the above study on stationary phase, it was concluded related compound-c in Ziprasidone hydrochloride monohydrate were well separated from each other in Zorbax RX C8 150 X 4.6 mm I.D., 5.0µm column Optimized method: Based on the above study, the below mentioned HPLC parameters was chosen for the separation and quantification of related compound-c and Ziprasidone hydrochloride monohydrate. Column : Zorbax RX C8 150 x 4.6 mm I.D., 5.0μm column Buffer preparation Mobile phase-a Mobile phase-b Sample preparation Auto sampler Wavelength : ddissolved 6.8 g/l of mono basic potassium phosphate in adjust with 5N of potassium hydroxide to a ph 6.0 : A degassed mixture of buffer: methanol: acetonitrile in the ratio of 40:15:45 (v/v/v) : Acetonitrile (100%) : 45 mg in 100 ml of diluent 5 o C : 229 nm Chapter-7 Page 223
13 Flow rate : 1.0 ml/min Oven temperature Injection volume Run time : 35 o C : 20μL : 65min Diluent : Methanol: water : hydrochloric acid (80:20:0.04) Elution : Gradient Gradient programme : Mobile phase-a Mobile phase-b Time in min (%) (%) a) Reference stock solution: Weighed about each 18 mg of Ziprasidone hydrochloride monohydrate working standard and related compound-d into 100 ml volumetric flask, dissolved and diluted to volume with diluent and mixed well (0.18mg/mL). b) Reference Solution (0.2%): Diluted 0.5 ml of reference stock solution to 100 ml with diluent ( mg/ml). c) Preparation of Sample solution: Accurately weighed 45 mg of sample into 100 ml volumetric flask, dissolved and diluted to volume with diluent. Procedure: Injected all above solutions once and reference solution six times and calculated the system suitability parameters i.e. the theoretical plates, Tailing factor, %RSD for reference solution. System suitability criteria: % RSD for six replicate injections of reference solution should be not more than Chapter-7 Page 224
14 The tailing factor for Ziprasidone hydrochloride monohydrate peak reference solution should be not more than 1.5. The number of theoretical plates for Ziprasidone hydrochloride monohydrate peak reference solution should be not less than Table -7.2: Specification: S. No Name of the impurity Specification 01 Related compound-c Not more than 0.20% Calculation: calculate the impurity using below formula: Related compound- C area in test solution 1 Related compound C = X X 0.2 Avg. area of Ziprasidone peak in reference solution RRF Total impurities: % known impurities + % other unknown impurities calculated by area normalization. RRF for related compound-c: 0.42 RRT for related compound-c: 2.70 Figure- 7.6: A typical HPLC Chromatogram of diluent. Chapter-7 Page 225
15 Figure- 7.7: A typical HPLC Chromatogram of reference solution (0.2%). Figure- 7.8: A typical HPLC Chromatogram of Ziprasidone hydrochloride monohydrate as such sample. Figure- 7.9: A typical HPLC Chromatogram of Ziprasidone hydrochloride monohydrate and all impurities blend solution. Chapter-7 Page 226
16 7.5. RESULTS AND DISCUSSION Method validation: Analytical method validation was performed as per ICH and USFDA guidelines with specificity, precision, accuracy, linearity, limit of detection, limit of quantification, ruggedness and robustness Related substances by HPLC: System suitability: a) Reference stock solution: Weighed about each 18 mg of Ziprasidone hydrochloride monohydrate working standard and related compound-d into 100 ml volumetric flask, dissolved and diluted to volume with diluent and mixed well (0.18mg/mL). b) Reference solution (0.2%): Diluted 0.5mL of reference stock solution to 100 ml with diluent ( mg/ml). c) Preparation of sample solution: Transferred 45mg of sample into 100mL volumetric flask, dissolved and diluted to volume with diluent. Injected all above solutions once and calculated the system suitability parameters i.e. the resolution between adjacent peaks, Tailing factor and tangent for Ziprasidone hydrochloride monohydrate. Conclusion: Under optimized Chromatographic conditions, related compound-d and Ziprasidone hydrochloride monohydrate, were separated well, retention times being about and 5.70 min, respectively. The system suitability results are given in table-7.3. Table- 7.3: System suitability results: S. No Name Retention Relative retention % RSD Theoretical Tailing time(min) time(min) plates(n) factor( T) 01 Ziprasidone reference solution Related compound- D Chapter-7 Page 227
17 Specificity: a) Thermal degradation: Accurately weighed 1 gm of Ziprasidone hydrochloride monohydrate sample is taken and kept under thermal condition i.e., at 105 C for 7days and sample collected after 48hours and sample analysed related compound -C by HPLC and checked for % degradation and determine the peak purity of main peak. Observation: Ziprasidone hydrochloride monohydrate sample is stable under thermal condition. b) Photo degradation: Weighed 1 gm of sample is taken and kept in UV chamber i.e., at 254 nm for 48 hours and sample collected after 48 hours and sample analyzed. Observation: A Ziprasidone hydrochloride monohydrate sample is stable under photo condition. c) Acid hydrolysis: Sample was dissolved in 0.1N HCl at room temperature and collected the sample after 30minutes. The 30 minutes sample was analyzed for related compound -C by HPLC and checked for % degradation and determine the peak purity of main peak. Observation: Ziprasidone hydrochloride monohydrate sample is stable under acid hydrolysis. d) Base hydrolysis: Sample was dissolved in 0.1N NaOH at room temperature and collected the sample after 1hr. The 1hr sample was analyzed for related compound -C by HPLC and checked for % degradation and determine the peak purity of main peak. As 1 hour sample was found at RRT 5.2 impurity only observed as 0.06% and all other individual unspecified impurities eluting after Ziprasidone hydrochloride monohydrate are detected less than disregard limit. Hence, sample was dissolved in 0.1N NaOH and reflux at 70 o C. Collected the sample after 12 hours and analyzed for related compound-c by HPLC. Chapter-7 Page 228
18 Calculated the % degradation of related compound-c, unspecified impurity and determine the peak purity of Ziprasidone hydrochloride monohydrate peak. Observation: Ziprasidone hydrochloride monohydrate was degraded under base hydrolysis. e) Oxidation degradation: Sample was dissolved in 3% H2O2 in dark at room temperature up to 24 hours and samples were analyzed for related compound-c by HPLC and checked for % degradation and determine the peak purity of main peak. Note: Initial sample was dissolved in formic acid and found Ziprasidone hydrochloride monohydrate main peak is completely degraded. Hence, experiments were conducted without co-solvent for Water, base, acid and oxidation. Observation: Ziprasidone hydrochloride monohydrate was degraded to under peroxide solution. f) Water hydrolysis: Sample was dissolved in water and refluxed at 70 C temperature for 12 hours. 12 th hour, sample was analyzed for related compound-c by HPLC and checked for % degradation and determine the peak purity of main peak. Observation: Ziprasidone hydrochloride monohydrate was not degraded to under water hydrolysis. Conclusion: Related compound-c found to be not degraded under the all stress study conditions. Un specified impurity eluting after Ziprasidone hydrochloride monohydrate peak: Found to be degraded unspecified impurities eluting after Ziprasidone hydrochloride monohydrate peak in base degradation. The un specified impurity was found to be degraded drastically from not detected to 1.02% at about RRT 6.07 minutes and 0.90% at about RRT 5.00 minutes under stressed condition of base hydrolysis (0.1N NaOH) at 70 o C temperature. Chapter-7 Page 229
19 Ziprasidone hydrochloride monohydrate: However, Ziprasidone hydrochloride monohydrate peak found drastically degraded under stressed condition of 0.1N HCl and 0.1N NaOH and not degraded under the stress condition of UV, Visible, heat, water hydrolysis and oxidation. The degradation results are given in below table Table- 7.4: Ziprasidone hydrochloride monohydrate degradation data : Stressed condition Time (hrs) % Purity Thermal degradation 7 x 24hrs Photo degradation 7 x 24hrs Acid hydrolysis 0.5hrs Base hydrolysis 12hrs Oxidation degradation 24hrs 90.0 Water hydrolysis 12 hrs Figure- 7.10: A typical HPLC Chromatogram of thermal degradation sample. Chapter-7 Page 230
20 Figure- 7.11: A typical HPLC Chromatogram of photo degradation sample. Figure- 7.12: A typical HPLC Chromatogram of acid degradation sample. Figure-7.13: A typical HPLC Chromatogram of base degradation sample. Chapter-7 Page 231
21 Figure- 7.14: A typical HPLC Chromatogram of oxidation degradation sample. Figure- 7.15: A typical HPLC Chromatogram of water hydrolysis degradation sample Limit of Detection and Limit of Quantification: a) LOQ solution-1 preparation (0.05%): Transferred 5.0µL of related compound- C stock solutions into 10mL volumetric flask, dissolved and diluted to volume with diluent. b) LOQ solution-2 preparation: Transferred 5.0µL of related compound-c stock solutions into 10mL volumetric flask, dissolved and diluted to volume with diluent. Chapter-7 Page 232
22 c) LOD solution-1 preparation: Transferred 3.3mL of above LOQ solution-2 stock solutions into 10mL volumetric flask, dissolved and diluted to volume with diluent. Injected all above solutions and calculated the Limit of detection and Limit of quantification for each impurity. Conclusion: The LOD for related compound-c was found 0.013% respectively. The LOQ for related compound-c was found to be 0.05 % respectively. The results are summarized in the table Table- 7.5: Limit of detection and Limit of Quantification data: Concentration Related compound-c (%) LOD LOQ Precision and accuracy at Limit of Quantification level: a) Related compound-c stock Solution preparation: Transferred 45mg of related compound-c into 100mL volumetric flask, containing 20mL of diluent dissolved and diluted to volume with diluent. Prepared six times the solution as mentioned above and inject all the above solutions each preparation once, calculated the % RSD for six preparations for impurity. Accuracy: b) Sample + related compound-c stock solution preparation: Accurately weighed 45mg of sample into 100mL volumetric flask, dissolved in 50mL of diluent and added 50µL of related compound-c dissolved and diluted to volume with diluent. c) Sample solution preparation: Weighed 45mg of sample into 100mL volumetric flask, dissolved and diluted to volume with diluent. Chapter-7 Page 233
23 Prepared three times the solution as mentioned above and inject each preparation once and calculated the % recovery for related compound-c at Limit of Quantification level. Conclusion: The repeatability and recovery at the LOQ concentrations for related compound-c were 3.7% and 105.7% respectively. The results are summarized in the table Table- 7.6: Precision and accuracy at Limit of Quantification level data: S. No Impurity % RSD (n=6) % Recovery (n=3) 1 Related compound-c Linearity: a) Linearity solution-1 (0.049%): Transferred 5µL related compound-c stock solution into 10mL volumetric flask, containing 5mL of diluent dissolved and diluted to volume with diluent. b) Linearity solution-2 (0.099%): Transferred 10µL of related compound-c stock solution into 10mL volumetric flask, containing 5mL of diluent dissolved and diluted to volume with diluent. c) Linearity solution-3(0.148%): Transferred 15µL of related compound-c stock solution in to 10mL volumetric flask, containing 5mL of diluent dissolved and diluted to volume with diluent. d) Linearity solution-4 (0.198%): Transferred 20µL of related compound-c stock solution into 10mL volumetric flask, containing 5mL of diluent dissolved and diluted to volume with diluent. e) Linearity solution-5 (0.247%): Transferred 24.7µL of related compound-c stock solution into 10mL volumetric flask, containing 5mL of diluent dissolved and diluted to volume with diluent. f) Linearity solution-6(0.297%): Accurately transferred 29.7µL of related compound-c stock solution into a 10mL volumetric flask, containing 5mL of diluent dissolved and diluted to volume with diluent. Injected all above Chapter-7 Page 234
24 solutions each preparation once and calculated the Linearity parameters i.e. correlation coefficient, slope and intercept for impurity. Conclusion: Linearity established for related compound-c at 0.049%, 0.099%, 0.148%, 0.198%, 0.247% and 0.297%. The correlation coefficient (r) are more than The above result reveal that method is linear, results are summarized in purity wise and presented in table-7.7. Table- 7.7: Ziprasidone related compound-c linearity data: S. No Level (%) Concentration (%) Area of related compound-c 1 LOQ Correlation coefficient(r) Slope Y-Intercept % 100 Y-Intercept 1.70 Chapter-7 Page 235
25 Figure- 7.15: Ziprasidone related compound-c linearity graph Accuracy: a) Accuracy solution-1 preparation (LOQ): Accurately weighed 45mg of sample into 100 ml volumetric flask, dissolved in 30mL of diluent and added 50µL impurity stock solution, dissolved and diluted to volume with diluent. Three solutions prepared as mentioned above. b) Accuracy solution-2 preparation- (50%): Weighed 45 mg of sample into 100 ml volumetric flask, dissolved in 30 ml of diluent and added 100µL of impurity stock solution, dissolved and diluted to volume with diluent. Three solutions prepared as mentioned above. c) Accuracy solution-3 preparation (100%): Transferred 45 mg of sample into 10 ml volumetric flask, dissolved in 5mL of diluent and added 200µL of impurity stock solution, dissolved and diluted to volume with diluent. Three solutions prepared as mentioned above. d) Accuracy solution-4 preparation (150%): Accurately weighed 45mg of sample into 10 ml volumetric flask, dissolved in 5mL of diluent and added 300µL of impurity stock solution, dissolved and diluted to volume with diluent. Three solutions prepared as mentioned above. Chapter-7 Page 236
26 Injected each above preparation once and calculated the % recovery for Ziprasidone related compound-c. Conclusion: The percentage recovery of related compound-c in Ziprasidone hydrochloride monohydrate samples is shown in table Table- 7.8: % Recovery in accuracy : Concentration Related compound-c (%) LOQ % % % Precision: a) Sample preparation: Weighed 45mg of sample into 100mL volumetric flask,dissolved and diluted to volume with diluent. b) Sample + LOQ Solution spiked preparation: Accurately weighed 45mg of sample into a 100mL volumetric flask, dissolved in 30mL of diluent added 200µL of impurity stock solution dissolved and diluted to volume with diluent. Prepared the solution six times as mentioned above. Injected all above sample preparations and calculated the % RSD for impurity. Conclusion: The precision of the related substance method was checked by injecting six individual preparations of Ziprasidone hydrochloride monohydrate spiked with 0.20% related compound-c. The % R.S.D of the area for of related compound-c was calculated. The results was summarized in the table-7.9, Chapter-7 Page 237
27 Table- 7.9: Precision data: S. No Preparation Related compound-c area % Average Standard deviation %RSD Robustness: Flow variation: a) Sample solution preparation: Weighed 5 mg of sample into 100mL volumetric flask, dissolved and diluted to volume with diluent. b) Sample % spiked preparation: Transferred 45 mg of sample into 100mL volumetric flask, dissolved in 5 ml of diluent added 200µL of impurity stock solution dissolved and diluted to volume with diluent. Injected the above sample solution at flow rates 0.8mL/min and at 1.2mL/min and observed the system suitability parameters and impurities relative retention times and compared with 1.0mL/min results. Temperature variation: a) Sample solution preparation: Transferred 45mg of sample into 100mL volumetric flask, dissolved and diluted to volume with diluent. b) Sample % spiked preparation: Accurately weighed 45mg of sample into 100mL volumetric flask, dissolved in 30mL of diluent added 200µL of impurity stock solution dissolved and diluted to volume with diluent Injected the above sample solution at temperature 30 C and at 40 C and observed the system suitability parameters and impurities relative retention times and compared with 35 C results. Chapter-7 Page 238
28 ph variation: a) Sample solution preparation: Weighed 45mg of sample into 100mL volumetric flask, dissolved and diluted to volume with diluent. b) Sample % spiked preparation: Accurately weighed 45mg of sample into 100mL volumetric flask, dissolved in 30 ml of diluent added 200µL of impurity stock solution dissolved and diluted to volume with diluent. Injected the above sample solution at ph 5.8 and at 6.2 and observed the system suitability parameters and impurities relative retention times and compared with 6.0 results. Conclusion: The results are summarized in the table Table -7.10: Robustness data: Parametr 30 C 40 C ph at ph at As ml/min ml/min such Tailing factor for Ziprasidone reference solution % RSD for Ziprasidone reference solution % RSD for Ziprasidone related compound-d Solution stability: Sample solution preparation: Accurately weighed 45mg of sample into a 100mL volumetric flask, dissolved and diluted to volume with diluent. Injected the solution for 0 hrs(initial), 12hrs, 24 hrs and 48 hrs and performed the impurity content. Conclusion: Related compound-c is not increased and other impurities are also not observed during the solution stability and mobile phase stability experiments when performed using the related substance method. The solution stability and mobile Chapter-7 Page 239
29 phase stability experiment data confirms that the sample solutions and mobile phases used during the related substance determination were stable for at least 48 hours. The results are summarized in the table Table- 7.11: Solution stability data: Duration Related compound-c (%) Sample solution initial After 12 hrs After 24 hrs After 48 hrs Table -7.12: Mobile phase stability data: Duration Related compound-c (%) Sample solution initial After 12 hrs After 24 hrs After 48 hrs Batch analysis: Using the above validated method, Ziprasidone hydrochloride monohydrate sample was analyzed and the data is furnished in table Table- 7.13: Batch analysis data Lot Number Related compound-c SUMMARY AND CONCLUSION The simple isocratic HPLC method for quantification of related compound-c in Ziprasidone hydrochloride monohydrate. Related compound-c is precise, accurate, rapid and specific. The method was fully validated showing satisfactory data for all the method validation parameters tested. The developed method can be used for regular samples and stability samples analysis also. Chapter-7 Page 240
30 7.7. REFERENCES 1. Daniel oakowiecki, and Krzysztof cal.development of rapid and robust stability-indicating method for analysis of Ziprasidone hydrochloride and freebase as drug substance and in medicines by UPLC. Pelpioska 19, starogard gdaoski, poland. Hallera107, Gdaosk, Poland. 2. T.Kaleemullah1, Mansur Ahmed, Hemant Kumar sharma, KVSN Raju, M.Narendra Kumar. Development and validation of gas chromatography method for low level detection of residual methyl chloride, ethyl chloride and isopropyl chloride in Ziprasidone hydrochloride scholars Research Library Der Pharma Chemica, 2011, 3 (6): ISSN XCODEN(USA): PCHHAX. 3. B. Sudha Rani and P. Venkata Reddy. Volume 3 (2006), Issue 3, Pages ,DOI: /2006/ Volume 3 (2006), Issue 3, Pages , doi: /2006/ Medikondu Kishorea, Y.Hanumantharao. A validated spectrophotometric methods for the determination of Ziprasidone as hydrochloride in bulk and pharmaceutical formulations. International Journal of Chemical and analytical Science 2010, 1(7), , ISSN: A. Singh, B. M. Rao, G. R. Deshpande, S. Sangaraju, M.K. Srinivasu, M. Lalitha Devi, P. V. V. Satyanarayana and K.B.Chandrasekhar. A rapid stability- Indicating LC method for Ziprasidone hydrochloride. Volume 65,numbers 3-4 (2007), ,DOI: /s S.Uma Devi, E. Pushpa Latha, C.V.Nagendra Kumar Guptha, P. Ramalingam, Development and validation of HPTLC method for estimation of Ziprasidone hydrochloride in bulk and pharmaceutical dosage forms. ISSN Ganji ramanaiah, Dr.D.Ramachandran,G.srinivas, Jayapal gowardhane, Purnachanda rao. Development and validation of a rapid uv-spectroscopic method for the estimation of Ziprasidone hydrochloride monohydrate in drug substance and its dosage forms. Issn vol 4, issue 2, M.Gnana ruba priya, M. Karikalan, S. Asadulla, S. Rajesh, J. Siva rama krishna and S. Vijay sridhar. Development and method validation using HPLC for assay Chapter-7 Page 241
31 of Ziprasidone capsule,ijpsr (2011), vol. 2, issue 9(research), ISSN: K. Srinivasa rao, K.Srinivas, S. Satyanarayana raju, new RP-HPLC method For the estimation of Ziprasidone hydrochloride In pharmaceutical dosage forms. Vol. 7, Issue 8, J.D.Chudasama, K.P.Channabasavaraj, J. S. Modiya, T. T. Mani.Development and validation of three new assay methods for Ziprasidone hydrochloride. monohydrate using UV-Spectrophotometry, IJPRD, 2011; Vol 3(3): 8; May 2011 (57-63) International Standard Serial Number Shilpi agarwal1,vinod K. Gupta2, Barkha Singhal3, potentiometric assay of antipsychotic drug (Ziprasidone hydrochloride) in pharmaceuticals, serum and urine..1, J. Electrochem. Sci., 6 (2011) Chapter-7 Page 242
CHAPTER INTRODUCTION OF DOSAGE FORM AND LITERATURE REVIEW
132 CHAPTER 6 DEVELOPMENT AND VALIDATION OF A STABILITY-INDICATING RP-HPLC METHOD FOR SIMULTANEOUS DETERMINATION OF PARACETAMOL, TRAMADOL HYDROCHLORIDE AND DOMPERIDONE IN A COMBINED DOSAGE FORM 6.1 INTRODUCTION
More informationCHAPTER INTRODUCTION OF DOSAGE FORM AND LITERATURE REVIEW
51 CHAPTER 2 SIMULTANEOUS ESTIMATION OF PIOGLITAZONE, GLIMEPIRIDE AND GLIMEPIRIDE IMPURITIES IN COMBINATION DRUG PRODUCT BY A VALIDATED STABILITY-INDICATING RP-HPLC METHOD 2.1 INTRODUCTION OF DOSAGE FORM
More informationJournal of Chemical and Pharmaceutical Research, 2017, 9(9): Research Article
Available online www.jocpr.com Journal of Chemical and Pharmaceutical Research, 2017, 9(9):70-80 Research Article ISSN : 0975-7384 CODEN(USA) : JCPRC5 Development and Validation of Stability Indicating
More informationDevelopment and validation of stability indicating RP-LC method for estimation of calcium dobesilate in pharmaceutical formulations
Available online at www.scholarsresearchlibrary.com Scholars Research Library Der Pharmacia Lettre, 2016, 8 (11):236-242 (http://scholarsresearchlibrary.com/archive.html) ISSN 0975-5071 USA CODEN: DPLEB4
More informationPelagia Research Library
Available online at www.pelagiaresearchlibrary.com Der Pharmacia Sinica, 2014, 5(5):91-98 ISSN: 0976-8688 CODEN (USA): PSHIBD A novel RP-HPLC method development and validation of Perindopril Erbumine in
More informationDevelopment and Validation for Simultaneous Estimation of Sitagliptin and Metformin in Pharmaceutical Dosage Form using RP-HPLC Method
International Journal of PharmTech Research CODEN (USA): IJPRIF ISSN : 0974-4304 Vol.5, No.4, pp 1736-1744, Oct-Dec 2013 Development and Validation for Simultaneous Estimation of Sitagliptin and Metformin
More informationInt. J. Pharm. Sci. Rev. Res., 30(1), January February 2015; Article No. 32, Pages:
Research Article Development and Validation of Stability Indicating RP-HPLC Method for the Estimation of Cilnidipine in Bulk and Pharmaceutical Dosage Form. Atul Kadam* 1, Dr. (Mrs.) Purnima Hamrapurkar
More informationJournal of Chemical and Pharmaceutical Research
Available on line www.jocpr.com Journal of Chemical and Pharmaceutical Research ISSN No: 0975-7384 CODEN(USA): JCPRC5 J. Chem. Pharm. Res., 2011, 3(1):138-144 Simultaneous RP HPLC determination of Latanoprost
More informationA New Stability-Indicating and Validated RP-HPLC Method for the Estimation of Liraglutide in Bulk and Pharmaceutical Dosage Forms
OPEN ACCESS Eurasian Journal of Analytical Chemistry ISSN: 1306-3057 2017 12(2):31-44 DOI 10.12973/ejac.2017.00152a A New Stability-Indicating and Validated RP-HPLC Method for the Estimation of Liraglutide
More informationRP-HPLC Method Development and Validation of Abacavir Sulphate in Bulk and Tablet Dosage Form
RP-HPLC Method Development and Validation of Abacavir Sulphate in Bulk and Tablet Dosage Form S. LAVANYA* 1, SK. MANSURA BEGUM 1, K. NAGAMALLESWARA RAO 2, K. GAYATHRI DEVI 3 Department of pharmaceutical
More information(ACE) inhibitor class that is primarily used in cardiovascular. conditions. Lisinopril was introduced into therapy in the early
107 CHAPTER 5 METHODDEVOLOPMENT FOR SIMULTANEOUS DETERMINATION OF LISINOPRIL AND HYDROCHLOROTHIAZIDE RELATED IMPURITIES IN LISINOPRIL AND HYDROCHLOROTHIAZIDE COMBINED TABLET DOSAGE FORMS USING HPLC 108
More informationCHAPTER-5. Sumatriptan Succinate
110 CHAPTER-5 Sumatriptan Succinate 111 CHAPTER-5 Chapter-5 : Sumatriptan succinate S. No. Name of the Sub- Title Page No. 5.1 Introduction 112-113 5.2 Experimental 114-121 5.3 Method validation Procedure
More informationAvailable online at Scholars Research Library
Available online at www.scholarsresearchlibrary.com Scholars Research Library Der Pharmacia Lettre, 2015, 7 (3):157-161 (http://scholarsresearchlibrary.com/archive.html) ISSN 0975-5071 USA CODEN: DPLEB4
More informationDevelopment and validation of related substances method for Varenicline and its impurities
Available online at www.scholarsresearchlibrary.com Scholars Research Library Der Pharmacia Lettre, 2016, 8 (1):304-309 (http://scholarsresearchlibrary.com/archive.html) ISSN 0975-5071 USA CODEN: DPLEB4
More informationMETHOD DEVELOPMENT AND VALIDATION BY RP-HPLC FOR ESTIMATION OF ZOLPIDEM TARTARATE
WORLD JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES Ramalakshmi et al. SJIF Impact Factor 6.647 Volume 7, Issue 2, 1010-1018 Research Article ISSN 2278 4357 METHOD DEVELOPMENT AND VALIDATION BY RP-HPLC
More informationAsian Journal of Pharmaceutical Analysis and Medicinal Chemistry Journal home page:
Research Article CODEN: AJPAD7 ISSN: 2321-0923 Asian Journal of Pharmaceutical Analysis and Medicinal Chemistry Journal home page: www.ajpamc.com ANALYTICAL METHOD DEVELOPMENT AND VALIDATION OF GEFITINIB
More informationA simple validated RP-HPLC method for quantification of sumatriptan succinate in bulk and pharmaceutical dosage form
IJPAR Vol.4 Issue 1 Jan-Mar-2015 Journal Home page: ISSN: 2320-2831 Research article Open Access A simple validated RP-HPLC method for quantification of sumatriptan succinate in bulk and pharmaceutical
More informationHyderabad, India. Department of Pharmaceutical Chemistry, Glocal University, Saharanpur, India.
International Journal On Engineering Technology and Sciences IJETS RP-HPLC Method development and validation for the Simultaneous Estimation of Metformin and Empagliflozine in Tablet Dosage Form Shaik
More informationDEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR ESTIMATION OF LACOSAMIDE IN BULK AND ITS PHARMACEUTICAL FORMULATION
http://www.rasayanjournal.com Vol.4, No.3 (2011), 666-672 ISSN: 0974-1496 CODEN: RJCABP DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR IN BULK AND ITS PHARMACEUTICAL FORMULATION V.Kalyan Chakravarthy*
More informationScholars Research Library. Der Pharmacia Lettre, 2016, 8 (6): (http://scholarsresearchlibrary.com/archive.html)
Available online at www.scholarsresearchlibrary.com Scholars Research Library Der Pharmacia Lettre, 2016, 8 (6):217-223 (http://scholarsresearchlibrary.com/archive.html) ISSN 0975-5071 USA CODEN: DPLEB4
More informationPelagia Research Library
Available online at www.pelagiaresearchlibrary.com Der Pharmacia Sinica, 2015, 6(1):6-10 ISSN: 0976-8688 CODEN (USA): PSHIBD Validated RP-HPLC method for simultaneous estimation of metformin hydrochloride
More informationRao and Gowrisankar: Stability-indicating RP-HPLC Method for Pseudoephedrine, Ambroxol and Desloratadine
Research Paper Development and Validation of Stability-indicating RP- HPLC Method for the Estimation of Pseudoephedrine, Ambroxol and Desloratadine in Bulk and Tablet Dosage Forms N. MALLIKARJUNA RAO*
More informationScholars Research Library. Der Pharmacia Lettre, 2015, 7 (5):44-49 (
Available online at www.scholarsresearchlibrary.com Scholars Research Library Der Pharmacia Lettre, 2015, 7 (5):44-49 (http://scholarsresearchlibrary.com/archive.html) ISSN 0975-5071 USA CODEN: DPLEB4
More informationDhull Rohit, Kumar Sanjay, Jalwal Pawan Department of Chemistry, OPJS Churu, Rajasthan, India
International Journal of Advanced Science and Research ISSN: 2455-4227, Impact Factor: RJIF 5.12 www.allsciencejournal.com Volume 2; Issue 2; March 2017; Page No. 31-40 Validated gradient stability indicating
More informationRP-HPLC Analysis of Temozolomide in Pharmaceutical Dosage Forms
Asian Journal of Chemistry Vol. 22, No. 7 (2010), 5067-5071 RP-HPLC Analysis of Temozolomide in Pharmaceutical Dosage Forms A. LAKSHMANA RAO*, G. TARAKA RAMESH and J.V.L.N.S. RAO Department of Pharmaceutical
More informationSimultaneous estimation of Metformin HCl and Sitagliptin in drug substance and drug products by RP-HPLC method
International Journal of Chemical and Pharmaceutical Sciences 2017, Mar., Vol. 8 (1) ISSN: 0976-9390 IJCPS Simultaneous estimation of Metformin HCl and Sitagliptin in drug substance and drug products by
More informationInternational Journal of Pharma and Bio Sciences DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR THE ESTIMATION OF STRONTIUM RANELATE IN SACHET
International Journal of Pharma and Bio Sciences RESEARCH ARTICLE ANALYTICAL CHEMISTRY DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR THE ESTIMATION OF STRONTIUM RANELATE IN SACHET K.MYTHILI *, S.GAYATRI,
More informationCHAPTER 2 SIMULTANEOUS DETRMINATION OF ANASTROZOLE AND TEMOZOLOMIDE TEMOZOLOMIDE CAPSULES 20 MG AND ANASTROZOLE TABLETS 1 MG
CHAPTER 2 SIMULTANEOUS DETRMINATION OF ANASTROZOLE AND TEMOZOLOMIDE IN TEMOZOLOMIDE CAPSULES 20 MG AND ANASTROZOLE TABLETS 1 MG ANALYTICAL METHOD VALIDATION REPORT FOR ASSAY 43 2.1 Introduction Analytical
More informationAMERICAN JOURNAL OF BIOLOGICAL AND PHARMACEUTICAL RESEARCH
AMERICAN JOURNAL OF BIOLOGICAL AND PHARMACEUTICAL RESEARCH e-issn - 2348-2184 Print ISSN - 2348-2176 Journal homepage: www.mcmed.us/journal/ajbpr VALIDATED RP-HPLC METHOD FOR SIMULTANEOUS ESTIMATION OF
More informationRP- HPLC and Visible Spectrophotometric methods for the Estimation of Meropenem in Pure and Pharmaceutical Formulations
International Journal of ChemTech Research CODEN( USA): IJCRGG ISSN : 0974-4290 Vol. 3, No.2, pp 605-609, April-June 2011 RP- HPLC and Visible Spectrophotometric methods for the Estimation of Meropenem
More informationStability indicating RP-HPLC method development and validation of Etizolam and Propranolol hydrochloride in pharmaceutical dosage form
World Journal of Pharmaceutical Sciences ISSN (Print): 2321-3310; ISSN (Online): 2321-3086 Published by Atom and Cell Publishers All Rights Reserved Available online at: http://www.wjpsonline.org/ Original
More informationIJPAR Vol.3 Issue 4 Oct-Dec-2014 Journal Home page:
IJPAR Vol.3 Issue 4 Oct-Dec-2014 Journal Home page: ISSN: 2320-2831 Research article Open Access Method development and validation of tenofovir disoproxil fumerate and emtricitabine in combined tablet
More informationNew RP-HPLC Method for the Determination of Fludarabine in Pharmaceutical Dosage Forms
Online : ISSN 2349-669X Print : ISSN 0973-9874 New RP-HPLC Method for the Determination of Fludarabine in Pharmaceutical Dosage Forms LAKSHMI B 1, *, RAMA KRISHNA K 2 AND JAYAVEERA K N 3 1. Department
More informationAvailable online Research Article
Available online www.jocpr.com Journal of Chemical and Pharmaceutical Research, 2016, 8(1):171-176 Research Article ISSN : 0975-7384 CODEN(USA) : JCPRC5 Reverse phase high performance liquid chromatography
More informationDevelopment and Validation of a Simultaneous HPLC Method for Quantification of Amlodipine Besylate and Metoprolol Tartrate in Tablets
Journal of PharmaSciTech 0; ():- Research Article Development and Validation of a Simultaneous HPLC Method for Quantification of Amlodipine Besylate and Metoprolol Tartrate in Tablets * Sayyed Hussain,
More informationSimultaneous Estimation of Gemcitabine Hydrochloride and Capecitabine Hydrochloride in Combined Tablet Dosage Form by RP-HPLC Method
ISSN: 0973-4945; CODEN ECJHAO E- Chemistry http://www.e-journals.net 2011, 8(3), 1212-1217 Simultaneous Estimation of Gemcitabine Hydrochloride and Capecitabine Hydrochloride in Combined Tablet Dosage
More informationA stability indicating RP-HPLC method for simultaneous estimation of darunavir and cobicistat in bulk and tablet dosage form
Available online at www.scholarsresearchlibrary.com Scholars Research Library Der Pharmacia Lettre, 2016, 8 (12):89-96 (http://scholarsresearchlibrary.com/archive.html) ISSN 0975-5071 USA CODEN: DPLEB4
More informationDevelopment and validation of RP-HPLC method for simultaneous estimation of gliclazide and metformin in pure and tablet dosage form
ISSN: 2320-2831 IJPAR Vol.3 Issue 4 Oct-Dec-2014 Journal Home page: Research article Open Access Development and validation of RP-HPLC method for simultaneous estimation of gliclazide and metformin in
More informationJournal of Chemical and Pharmaceutical Research
Available on line www.jocpr.com Journal of Chemical and Pharmaceutical Research ISSN No: 0975-7384 CODEN(USA): JCPRC5 J. Chem. Pharm. Res., 2011, 3(2):770-775 Validation of Rapid Liquid Chromatographic
More informationSUMMARY, CONCLUSION & RECOMMENDATIONS
196 Chapter-5 SUMMARY, CONCLUSION & RECOMMENDATIONS 197 CHAPTER 5 5.1 Summary, Conclusion and Recommendations Summary and Conclusion are drawn based on the work carried out by the author on development
More informationDEVELOPMENT AND VALIDATION OF RP-HPLC METHOD ESTIMATION OF TOLVAPTAN IN BULK PHARMACEUTICAL FORMULATION
http://www.rasayanjournal.com Vol.4, No.1 (2011), 165-171 ISSN: 0974-1496 CODEN: RJCABP DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR AND ITS PHARMACEUTICAL FORMULATION V. Kalyana Chakravarthy * and
More informationStress Degradation Studies And Validation Method For Quantification Of Aprepitent In Formulations By Using RP-HPLC
International Journal of ChemTech Research CODEN( USA): IJCRGG ISSN : 0974-4290 Vol.5, No.4, pp 1462-1468, April-June 2013 Stress Degradation Studies And Validation Method For Quantification Of Aprepitent
More informationInternational Journal of Research in Pharmaceutical and Nano Sciences Journal homepage:
Research Article CODEN: IJRPJK ISSN: 2319 9563 International Journal of Research in Pharmaceutical and Nano Sciences Journal homepage: www.ijrpns.com STABILITY INDICATING RP HPLC METHOD FOR DETERMINATION
More informationRP-HPLC METHOD DEVELOPMENT AND VALIDATION FOR THE ESTIMATION OF BACLOFEN IN BULK AND PHARMACEUTICAL DOSAGE FORMS
Int. J. Chem. Sci.: 11(1), 2013, 390-398 ISSN 0972-768X www.sadgurupublications.com RP-HPLC METHOD DEVELOPMENT AND VALIDATION FOR THE ESTIMATION OF BACLOFEN IN BULK AND PHARMACEUTICAL DOSAGE FORMS SAROJ
More informationMethod Development and Validation for Simultaneous Estimation of Atorvastatin and Ezetimibe in Pharmaceutical Dosage Form by HPLC
World Journal of Pharmaceutical Sciences ISSN (Print): 2321-3310; ISSN (Online): 2321-3086 Published by Atom and Cell Publishers All Rights Reserved Available online at: http://www.wjpsonline.org/ Original
More informationAsian Journal of Chemistry Vol. 21, No. 1 (2009),
Asian Journal of Chemistry Vol. 21, o. 1 (2009), 176-182 imultaneous Estimation of Related Impurities of Tizanidine Hydrochloride in its Active Pharmaceutical Ingradient by Reversed-Phase Liquid Chromatography
More informationWorld Journal of Pharmaceutical Research
World Journal of Pharmaceutical ReseaRch Volume 3, Issue 3, 4527-4535. Research Article ISSN 2277 715 DEVELOPMENT AND VALIDATION OF STABILITY INDICATING HPLC METHOD FOR ESTIMATION OF RAMOSETRON Zarana
More informationSanjog Ramdharane 1, Dr. Vinay Gaitonde 2
JPSBR: Volume 5, Issue 2: 2015 (151-155) ISS. 2271-3681 A ew Gradient RP- HPLC Method for Quantitative Analysis of : (3-luoro-4- Morpholin-4-yl-Phenyl)-Carbamic Acid Methyl Ester and its Related Substances
More informationSIMULTANEOUS ESTIMATION OF VALSARTAN AND HYDROCHLOROTHIAZIDE IN TABLETS BY RP-HPLC METHOD
170 Original Article SIMULTANEOUS ESTIMATION OF VALSARTAN AND HYDROCHLOROTHIAZIDE IN TABLETS BY RP-HPLC METHOD *Lakshmana Rao A, 1 Bhaskara Raju V *V.V. Institute of Pharmaceutical Sciences, Gudlavalleru,
More informationISSN (Print)
Scholars Academic Journal of Pharmacy (SAJP) Sch. Acad. J. Pharm., 2014; 3(3): 240-245 Scholars Academic and Scientific Publisher (An International Publisher for Academic and Scientific Resources) www.saspublisher.com
More informationInternational Journal of Applied Pharmaceutical Sciences and Research
International Journal of Applied Pharmaceutical Sciences and Research 2017; 2(3): 55-63 Anas et al/international Journal of Applied Pharmaceutical Sciences and Research 2017; 2(3): 55-63 International
More informationF. Al-Rimawi* Faculty of Science and Technology, Al-Quds University, P.O. Box 20002, East Jerusalem. Abstract
JJC Jordan Journal of Chemistry Vol. 4 No.4, 2009, pp. 357-365 Development and Validation of Analytical Method for Fluconazole and Fluconazole Related Compounds (A, B, and C) in Capsule Formulations by
More informationInternational Journal of Research in Pharmaceutical and Nano Sciences Journal homepage:
Research Article CODEX: IJRPJK ISSN: 2319 9563 International Journal of Research in Pharmaceutical and Nano Sciences Journal homepage: www.ijrpns.com HPLC METHOD DEVELOPMENT AND VALIDATION FOR SIMULTANEOUS
More informationTentu Nageswara Rao et al. / Int. Res J Pharm. App Sci., 2012; 2(4): 35-40
International Research Journal of Pharmaceutical and Applied Sciences Available online at www.irjpas.com Int. Res J Pharm. App Sci., 2012; 2(4):35-40 Research Article Estimation of Fesoterodine fumarate
More informationDevelopment and Validation of Stability Indicating HPTLC Method for Estimation of Seratrodast
ARC Journal of Pharmaceutical Sciences (AJPS) Volume 2, Issue 3, 2016, PP 15-20 ISSN 2455-1538 DOI: http://dx.doi.org/10.20431/2455-1538.0203004 www.arcjournals.org Development and Validation of Stability
More informationIJRPC 2013, 3(2) Nagamallika et al. ISSN: INTERNATIONAL JOURNAL OF RESEARCH IN PHARMACY AND CHEMISTRY
INTERNATIONAL JOURNAL OF RESEARCH IN PHARMACY AND CHEMISTRY Available online at www.ijrpc.com Research Article A VALIDATED STABILITY INDICATING RP-UPLC METHOD FOR SIMULTANEOUS DETERMINATION OF WATER SOLUBLE
More informationA Validated Stability Indicating RP-HPLC Method for Simultaneous Estimation of Valsartan and Clinidipine Combined Tablet dosage forms
World Journal of Pharmaceutical Sciences ISSN (Print): 2321-3310; ISSN (Online): 2321-3086 Published by Atom and Cell Publishers All Rights Reserved Available online at: http://www.wjpsonline.org/ Original
More informationAiro International Research Journal ISSN : Volume : 7 October 2015
Airo International Research Journal ISSN : 2320-3714 Volume : 7 October 2015 METHOD DEVELOPMENT AND VALIDATION FOR THE SIMULTANEOUS ESTIMATION OF ESCITALOPRAM OXALATE AND ETIZOLAM IN TABLET DOSAGE FORM
More informationIsocratic Reversed Phase Liquid Chromatographic Method Validation for the Determination of Cilostazol in Pure and Formulations
Human Journals Research Article October 2015 Vol.:4, Issue:3 All rights are reserved by Rambabu K et al. Isocratic Reversed Phase Liquid Chromatographic Method Validation for the Determination of Cilostazol
More informationInternational Journal of Farmacia
International Journal of Farmacia Journal Home page: www.ijfjournal.com Stability indicating analytical method development and validation for estimation of Sacubitril and Valsartan in bulk and pharmaceutical
More informationCHAPTER-6 IDENTIFICATION, AND CHARACTERISATION OF DEGRADATION IMPURITY IN VALSARTAN TABLETS
129 CHAPTER-6 IDENTIFICATION, AND CHARACTERISATION OF DEGRADATION IMPURITY IN VALSARTAN TABLETS 130 6.1. Introduction Valsartan is an orally active specific angiotensin II blocker effective in lowering
More informationANALYTICAL METHOD DEVELOPMENT AND VALIDATION FOR THE DETERMINATION OF ERLOTINIB HYDROCHLORIDE BULK AND IN PHARMACEUTICAL DOSAGE FORM
Saravanan et al Journal of Drug Delivery & Therapeutics; 2013, 3(1), 50-54 50 Available online at http://jddtonline.info RESEARCH ARTICLE ANALYTICAL METHOD DEVELOPMENT AND VALIDATION FOR THE DETERMINATION
More informationStability Indicating Method Development and Validation for the Estimation of Rotigotine by RP-HPLC in Bulk and Pharmaceutical Dosage Form
ORIENTAL JOURNAL OF CHEMISTRY An International Open Free Access, Peer Reviewed Research Journal www.orientjchem.org ISSN: 0970-020 X CODEN: OJCHEG 2015, Vol. 31, No. (4): Pg. 2499-2505 Stability Indicating
More informationAnkit et al Journal of Drug Delivery & Therapeutics; 2013, 3(2), Available online at RESEARCH ARTICLE
Ankit et al Journal of Drug Delivery & Therapeutics; 2013, 3(2), 26-30 26 Available online at http://jddtonline.info RESEARCH ARTICLE METHOD DEVELOPMENT AND ITS VALIDATION FOR QUANTITATIVE SIMULTANEOUS
More informationDevelopment and Validation of Stability Indicating HPLC method for Determination of Eperisone HCL in Bulk and in Formulation
Development and Validation of Stability Indicating HPLC method for Determination of Eperisone HCL in Bulk and in Formulation Sanjay Patil 1, Suvarna Vanjari 2, Rajendra Patil 3, Tushar Deshmukh 4 1 TSSM
More informationDEVELOPMENT AND STABILITY INDICATING HPLC METHOD FOR DAPAGLIFLOZIN IN API AND PHARMACEUTICAL DOSAGE FORM
International Journal of Applied Pharmaceutics ISSN- 0975-7058 Vol 9, Issue 5, 2017 Original Article DEVELOPMENT AND STABILITY INDICATING HPLC METHOD FOR DAPAGLIFLOZIN IN API AND PHARMACEUTICAL DOSAGE
More informationLamotrigine, 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine. novel anticonvulsant drug used in the treatment of epilepsy, bipolar
30 2.0 INTRODUCTION : Lamotrigine, 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine is novel anticonvulsant drug used in the treatment of epilepsy, bipolar disorder and pain syndromes. In psychiatry,
More informationEstimation of zolmitriptan by a new RP-HPLC method
Available online at www.scholarsresearchlibrary.com Scholars Research Library Der Pharmacia Lettre, 2012, 4 (3):1022-1026 (http://scholarsresearchlibrary.com/archive.html) ISSN 0975-5071 USA CODEN: DPLEB4
More informationS. G. Talele, D. V. Derle. Department of Pharmaceutics, N.D.M.V.P. College of Pharmacy, Nashik, Maharashtra, India
ORIGINAL ARTICLE Stability-indicating high-performance liquid chromatography (HPLC) method development and validation for the determination of quetiapine fumarate in bulk and dosage form S. G. Talele,
More informationJ Pharm Sci Bioscientific Res (4): ISSN NO
Development and Validation of Analytical Methods for Simultaneous Estimation of Pregabalin and Amitriptyline Hydrochloride in their Combined Marketed Dosage form ABSTRACT: Nikhilkumar Patel, Gurjit Kaur,
More informationDEVELOPMENT AND VALIDATION OF NEW HPLC METHOD FOR THE ESTIMATION OF PALIPERIDONE IN PHARMACEUTICAL DOSAGE FORMS
ISSN: 0974-1496 e-issn: 0976-0083 CODEN: RJCABP http://www.rasayanjournal.com http://www.rasayanjournal.co.in DEVELOPMENT AND VALIDATION OF NEW HPLC METHOD FOR THE ESTIMATION OF PALIPERIDONE IN PHARMACEUTICAL
More information36 J App Pharm Vol. 6; Issue 1: 36-42; January, 2014 Rao et al., 2014
36 J App Pharm Vol. 6; Issue 1: 36-42; January, 2014 Rao et al., 2014 Original Research Article SIMPLE AND RAPID LIQUID CHROMATOGRAPHIC METHOD FOR REAL-TIME QUANTIFICATION OF NAPROXEN / ESOMEPRAZOLE MAGNESIUM
More informationMethod Development and Validation for the Estimation of Saroglitazar in Bulk and Pharmaceutical Dosage Form by RP-HPLC
Original Research Method Development and Validation for the Estimation of Saroglitazar in Bulk and Pharmaceutical Dosage Form by RP-HPLC Hanumantha Rao K 1, Lakshmana Rao A 2,*, Chandra Sekhar KB 3 1 Assistant
More informationVALIDATED RP-HPLC METHOD FOR SIMULTANEOUS ESTIMATION OF DEXAMETHASONE AND GRANISETRON IN COMBINED DOSAGE FORMS
INTERNATIONAL JOURNAL OF RESEARCH IN PHARMACY AND CHEMISTRY Available online at www.ijrpc.com Research Article VALIDATED RP-HPLC METHOD FOR SIMULTANEOUS ESTIMATION OF DEXAMETHASONE AND GRANISETRON IN COMBINED
More informationISSN: ; CODEN ECJHAO E-Journal of Chemistry 2011, 8(3),
ISSN: 0973-4945; CODEN ECJHAO E- Chemistry http://www.e-journals.net 2011, 8(3), 1275-1279 Simultaneous Determination of Paracetamol, Phenylephrine Hydrochloride, Oxolamine Citrate and Chlorpheniramine
More informationIntroductionn Ilaprazole (ILA) is
Prajapathi et al: Simultaneous Estimation of IIaprazole and Domperi Internatio idone in Pharm maceutical Dosage Form 3549 onal Journal of Pharmaceutical Sciences and Nanotechnology Volume 9 Issue 6 November
More informationESTIMATION OF OXOLAMINE PHOSPHATE INDICATING HPLC METHOD: METHOD DEVELOPMENT AND VALIDATION
ISSN: 0974-1496 e-issn: 0976-0083 CODEN: RJCABP http://www.rasayanjournal.com http://www.rasayanjournal.co.in BY STABILITY INDICATING HPLC METHOD: METHOD DEVELOPMENT AND VALIDATION D. Murali* and C. Rambabu
More informationJournal of Pharmacreations
Journal of Pharmacreations ISSN: 2348-6295 Pharmacreations Vol.5 Issue 1 Jan- Mar- 2018 Journal Home page: www.pharmacreations.com Research article Open Access Method development and validation of apixaban
More informationJournal of Chemical and Pharmaceutical Research, 2018, 10(3): Research Article
Available online www.jocpr.com Journal of Chemical and Pharmaceutical Research, 2018, 10(3):142-147 Research Article ISSN : 0975-7384 CODEN(USA) : JCPRC5 Development of Reverse Phase HPLC Method and Validation
More informationRP-HPLC Method for the Simultaneous Estimation of Sitagliptin Phosphate and Metformin Hydrochloride in Combined Tablet Dosage Forms
Est. 1984 ORIENTAL JOURNAL OF CHEMISTRY An International Open Free Access, Peer Reviewed Research Journal www.orientjchem.org ISSN: 0970-020 X CODEN: OJCHEG 2012, Vol. 28, No. (1): Pg. 463-469 RP-HPLC
More informationANALYTICAL TECHNIQUES FOR THE QUALITY OF ANTI- AIDS DRUGS
Research Article N. Bala Krishna, IJPRBS, 2013; Volume 2(1): 63-77 ISSN: 2277-8713 IJPRBS N.BALAA KRISHNA, Dr. M.V.V NAGESWARA REDDY IJPRBS-QR CODE PAPER-QR CODE DEVELOPMENT OF NEW ANALYTICAL TECHNIQUES
More informationInternational Journal of Pharma and Bio Sciences
International Journal of Pharma and Bio Sciences RESEARCH ARTICLE PHARMACEUTICAL ANALYSIS DEVELOPMENT AND VALIDATION OF LIQUID CHROMATOGRAPHIC METHOD FOR ESTIMATION OF ESCITALOPRAM OXALATE IN TABLET DOSAGE
More informationVolume 6, Issue 1, January February 2011; Article-021
Research Article STABILITY-INDICATING RP-HPLC METHOD FOR DETERMINATION OF ZOLEDRONIC ACID AND THEIR DEGRADATION PRODUCTS IN ACTIVE PHARMACEUTICAL INGREDIENT AND PHARMACEUTICAL DOSAGE FORMS Praveen kumar.m
More informationDevelopment of RP-HPLC Method for Estimation of Valsartan and Hydrochlorothiazide in Tablets
2240 Int J Pharm Sci Nanotech Vol 6; Issue 4 December 2013 (extra issue) International Journal of Pharmaceutical Sciences and Nanotechnology Volume 6 Issue 4 December 2013 (extra issue) Research Paper
More information10 Kadam V. N. et al. Ijppr.Human, 2014; Vol. 1(2): 10-21 (Research Article) DEVELOPMENT AND VALIDATION OF ANALYTICAL METHODS FOR SIMULTANEOUS ESTIMATION OF VOGLIBOSE, GLIMEPIRIDE AND METFORMIN HYDROCHLORIDE
More informationAbstract. G. D. Patil 1, P. G. Yeole 1, Manisha Puranik 1 and S. J. Wadher 1 *
International Journal of ChemTech Research ISSN : 0974-4290 Vol.1,No.1,pp 16-26, Jan March 2009 A Validated Specific Reverse Phase Liquid Chromatographic Method for the Determination of Valacyclovir in
More informationDevelopment and validation of liquid chromatographic method for trazodone hydrochloride
Available online at www.scholarsresearchlibrary.com Scholars Research Library Der Pharmacia Lettre, 2012, 4 (6):1657-1664 (http://scholarsresearchlibrary.com/archive.html) ISS 0975-5071 USA CODE: DPLEB4
More informationA. Prameela Rani*, K.E.Pravallika, P.Ravi, O.Sasivardhan
International Journal of ChemTech Research CODEN (USA): IJCRGG, ISSN: 0974-4290, ISSN(Online):2455-9555 Vol.10 No.9, pp 467-476, 2017 Development and Validation of Stability Indicating RP-UPLC Method for
More informationScholars Research Library
Available online at www.scholarsresearchlibrary.com Der Pharmacia Lettre, 2011, 3(3): 350-356 (http://scholarsresearchlibrary.com/archive.html) ISSN 0975-5071 USA CODEN: DPLEB4 A new validated RP-HPLC
More informationEstimation of Zanamivir Drug present in Tablets using RP-HPLC Method
International Journal of PharmTech Research CODEN (USA): IJPRIF ISSN : 0974-4304 Vol. 3, No.1, pp 180-186, Jan-Mar 2011 Estimation of Zanamivir Drug present in Tablets using RP-HPLC Method Ravindra Reddy.Y*,
More informationDevelopment and Validation of RP-HPLC Method for the Simultaneous Estimation of Haloperidol and Trihexyphenidyl in API and Combined Tablet Dosage Form
Amulya ORIGINAL E et al.: Development RESEARCH and Validation of RP-HPLC Method ISSN: 2455-8095 doi: https://doi.org/10.21477/ijapsr.3.3.3 Development and Validation of RP-HPLC Method for the Simultaneous
More informationSTABILITY INDICATING HPLC METHOD FOR DETERMINATION OF RIMONABANT
Int. J. Chem. Sci.: 9(2), 2011, 481-488 ISSN 0972-768X www.sadgurupublications.com STABILITY INDICATING HPLC METHOD FOR DETERMINATION OF RIMONABANT Y. PADMAVATHI *, P. HARI KRISHNA and B. MADHAVA REDDY
More informationUttam Prasad Panigrahy 1, A. Sunil Kumar Reddy 2, 3 1 Department of Pharmaceutical Analysis and Quality Assurance, Malla Reddy College of Pharmacy,
IOSR Journal of Pharmacy and Biological Sciences (IOSR-JPBS) e-issn:2278-3008, p-issn:2319-7676. Volume 11, Issue 4 Ver. II (Jul. - Aug.2016), PP 49-69 www.iosrjournals.org A novel validated RP-UPLC-DAD
More informationAvailable online Research Article
Available online www.jocpr.com Journal of Chemical and Pharmaceutical Research, 2015, 7(9):951-960 Research Article ISSN : 0975-7384 CODEN(USA) : JCPRC5 Analytical method development and validation for
More informationDepartment of Pharmaceutical Analysis, Joginpally B.R. Pharmacy College, Yenkapally, Moinabad, R.R. Dist, A.P, India
World Journal of Pharmaceutical Sciences ISSN (Print): 2321-3310; ISSN (Online): 2321-3086 Published by Atom and Cell Publishers All Rights Reserved Available online at: http://www.wjpsonline.org/ Original
More informationScholars Research Library
Available online at www.scholarsresearchlibrary.com Scholars Research Library Der Pharmacia Lettre, 2010, 2(2): 294-299 (http://scholarsresearchlibrary.com/archive.html) ISSN 0975-5071 USA CODEN: DPLEB4
More informationReverse Phase HPLC Analysis of Atomoxetine in Pharmaceutical Dosage Forms
Asian Journal of Chemistry Vol. 21, No. 2 (2009), 829-833 Reverse Phase HPLC Analysis of Atomoxetine in Pharmaceutical Dosage Forms B.V.V.S. JAGADEESH, S. SATYANARAYANA RAJU, V.JAYATHIRTHA RAO and J.V.L.N.
More informationPelagia Research Library
Available online at www.pelagiaresearchlibrary.com Der Pharmacia Sinica, 2015, 6(4): 30-37 ISSN: 0976-8688 CODEN (USA): PSHIBD Development and validation of stability indicating RP-HPLC method for simultaneous
More informationSujatha and Pavani et.al. Indian Journal of Research in Pharmacy and Biotechnology ISSN: (Print) ISSN: (Online)
ANALYTICAL METHOD DEVELOPMENT AND VALIDATION OF AMITRIPTYLINE HYDROCHLORIDE AND CHLORDIAZEPOXIDE IN TABLET BY RP-HPLC Neeli Sujatha* K Haritha Pavani Department of Pharmaceutical Analysis and Quality Assurance,
More informationA Stability-Indicating RP-HPLC Method for the Quantitative Analysis of Meclizine Hydrochloride in Tablet Dosage Form
Journal of Chromatographic Science 2015;53:793 799 doi:10.1093/chromsci/bmu127 Advance Access publication February 1, 2015 Article A Stability-Indicating RP-HPLC Method for the Quantitative Analysis of
More information